Healthcare entity
medical-devices is the sole category represented across all 1 tracked stories. Boston Scientific Corporation is most often covered alongside FARAPULSE PFA, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention Boston Scientific Corporation, all published on March 23, 2026.
Last mentioned: Mar 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
medical-devices is the sole category represented across all 1 tracked stories. Boston Scientific Corporation is most often covered alongside FARAPULSE PFA, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention Boston Scientific Corporation, all published on March 23, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Boston Scientific Corporation. Shared-story counts are live from our verified record — not editorial picks.
Litigation Notice
Pomerantz LLP issues first public alert regarding the class action filing against Boston Scientific.
Form 8-K Filing
BSX files notice with the SEC regarding 'Other Events' involving executive shifts and operational updates.
Q4 2025 Earnings
Company reports financial results and provides updated guidance on clinical timelines.
AVANT GUARD Trial Pause
Boston Scientific announces a pause in its FARAPULSE PFA trial, citing the need for data review.
Pomerantz LLP has initiated a class action investigation and filing against Boston Scientific Corporation (BSX), alleging the medical device giant made misleading statements regarding its clinical trials and business prospects. The litigation follows a period of heightened volatility for the company's cardiovascular portfolio, specifically concerning the FARAPULSE PFA system and recent trial adjustments.
Boston Scientific Corporation is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
